Premium
New insights into the prevention and treatment of familial breast cancer
Author(s) -
Euhus David M.
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21664
Subject(s) - medicine , breast cancer , context (archaeology) , brca mutation , germline mutation , dna repair , mutation , germline , cisplatin , cancer , bioinformatics , oncology , cancer research , genetics , gene , chemotherapy , biology , paleontology
Individuals who inherit a deleterious mutation in BRCA1 or BRCA2 are at very high risk for breast cancer but there are several strategies available for successfully managing this risk. Breast cancers that develop in the context of germline BRCA gene mutation present challenges for management but also opportunities. DNA damaging agents, like cisplatin, and the new class of drugs called PARP inhibitors exploit the underlying defect in DNA damage repair to great effect. J. Surg. Oncol. 2011; 103:294–298. © 2011 Wiley‐Liss, Inc.